跳转至内容
Merck
CN

SML2848

尼达尼布

≥98% (HPLC), powder, VEGFR, PDGFR and FGFR inhibitor

别名:

(3Z)-2,3-二氢-3-[[[4-[甲基[2-(4-甲基-1-哌嗪基)乙酰基]氨基]苯基]氨基]苯基亚甲基]-2-氧代-1H-吲哚-6-羧酸甲酯, (Z)-3-(((4-(N-甲基-2-(4-甲基哌嗪-1-基)乙酰氨基)苯基)氨基)(苯基)亚甲基)-2-氧代二氢吲哚-6-羧酸甲脂, (Z)-3-[(4-{甲基-[2-(4-甲基哌嗪-1-基)乙酰基]氨基}苯基氨基)亚甲基]-2-氧代-2,3-二氢-1H-吲哚-6-羧酸甲酯, BIBF 1120, BIBF-1120, BIBF1120

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C31H33N5O4
化学文摘社编号:
656247-17-5
分子量:
539.62
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
MFCD11974012

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

尼达尼布, ≥98% (HPLC)

InChI

1S/C31H33N5O4/c1-34-15-17-36(18-16-34)20-27(37)35(2)24-12-10-23(11-13-24)32-29(21-7-5-4-6-8-21)28-25-14-9-22(31(39)40-3)19-26(25)33-30(28)38/h4-14,19,32H,15-18,20H2,1-3H3,(H,33,38)/b29-28-

InChI key

XZXHXSATPCNXJR-ZIADKAODSA-N

SMILES string

O=C(NC1=C2)/C(C1=CC=C2C(OC)=O)=C(C3=CC=CC=C3)\NC4=CC=C(C=C4)N(C(CN5CCN(CC5)C)=O)C

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

Quality Level

100

相关类别

Biochem/physiol Actions

口服活性，强效ATP竞争性VEGFR，FGFR，PDGFR，Flt3，Lck，Lyn，Src抑制剂，具有体内抗血管生成和抗纤维化功效。
尼达尼布（BIBF1120）是一种口服活性、强效ATP竞争性抑制剂，可抑制血管激酶VEGFR-1/2/3（IC50 = 34/21/13 nM）、FGFR-1/2/3/4（IC50 = 69/37/108/610 nM）、PDGFRα/β（IC50 = 59/65 nM）以及Flt-3、Lck、Lyn和Src（分别为IC50 = 26、16、195、156 nM），但不抑制33种其他激酶。尼达尼布在体内癌症和肺纤维化的培养物和动物模型中表现出抗血管生成和抗纤维化疗效。

signalword

Danger

Hazard Classifications

Acute Tox. 3 Oral - Eye Dam. 1 - Repr. 2 - Skin Irrit. 2 - STOT RE 1

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000478596
0000478595
0000478595
0000478596
0000419700

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Raquel Frenedoso da Silva et al.
Cell and tissue research, 379(2), 407-420 (2019-09-02)
The antiangiogenic therapy for prostate cancer with Nintedanib, a potent inhibitor of important growth factor receptors, has been proven to delay tumor progression and arrest tumor growth; thus, the aim herein is to evaluate Nintedanib effects on tumor cells, besides angiogenesis
Frank Hilberg et al.
Cancer research, 68(12), 4774-4782 (2008-06-19)
Inhibition of tumor angiogenesis through blockade of the vascular endothelial growth factor (VEGF) signaling pathway is a novel treatment modality in oncology. Preclinical findings suggest that long-term clinical outcomes may improve with blockade of additional proangiogenic receptor tyrosine kinases: platelet-derived
Roman C Brands et al.
Oncology letters, 18(3), 2220-2231 (2019-08-28)
Multidrug resistance (MDR) remains one of the major causes of suboptimal outcome following therapy in head and neck squamous cell carcinoma (HNSCC). ATP-binding cassette (ABC) transporters are overexpressed in HNSCC, which contributes to the limited effect of chemotherapeutic treatment. In
Elaine Reguera-Nuñez et al.
Angiogenesis, 22(4), 535-546 (2019-08-30)
In contrast to VEGF pathway-targeting antibodies, antiangiogenic tyrosine kinase inhibitors (TKIs) have failed to meet primary endpoints in almost all phase III clinical trials when combined with conventional chemotherapy. One exception is the combination of nintedanib and docetaxel as a
Emma Kulimova et al.
Molecular cancer therapeutics, 5(12), 3105-3112 (2006-12-19)
In acute myeloid leukemia (AML), receptor tyrosine kinase ligands promote growth and survival and contribute to AML-associated marrow neoangiogenesis. We have tested simultaneous inhibition of vascular endothelial growth factor, fibroblast growth factor, and platelet-derived growth factor receptor signaling by novel
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持